Search This Blog

Friday, May 23, 2014

Type 2 diabetes: European Commission approves Jardiance® (empagliflozin) tablets for use in adults in Europe (NYSE:LLY)

RIDGEFIELD, Conn. and INDIANAPOLIS, May 23, 2014 /PRNewswire/ -- The European Commission granted marketing authorization for Jardiance® (empagliflozin) tablets, a sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of type 2 diabetes mellitus (T2D) to improve glycemic control in adults in Europe, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) announced.



Type 2 diabetes: European Commission approves Jardiance® (empagliflozin) tablets for use in adults in Europe (NYSE:LLY)
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)